Leila A Haidari1, Shawn T Brown1, Marie Ferguson2, Emily Bancroft3, Marie Spiker2, Allen Wilcox3, Ramya Ambikapathi2, Vidya Sampath3, Diana L Connor4, Bruce Y Lee5. 1. HERMES Logistics Modeling Team, Baltimore, MD, United States; Pittsburgh Supercomputing Center, Carnegie Mellon University, Pittsburgh, PA, United States. 2. Global Obesity Prevention Center (GOPC), Johns Hopkins University, Baltimore, MD, United States; Department of International Health, Johns Hopkins University, Baltimore, MD, United States. 3. VillageReach, Seattle, WA, United States. 4. HERMES Logistics Modeling Team, Baltimore, MD, United States; Department of International Health, Johns Hopkins University, Baltimore, MD, United States. 5. HERMES Logistics Modeling Team, Baltimore, MD, United States; Global Obesity Prevention Center (GOPC), Johns Hopkins University, Baltimore, MD, United States; Department of International Health, Johns Hopkins University, Baltimore, MD, United States. Electronic address: brucelee@jhu.edu.
Abstract
BACKGROUND: Immunization programs in low and middle income countries (LMICs) face numerous challenges in getting life-saving vaccines to the people who need them. As unmanned aerial vehicle (UAV) technology has progressed in recent years, potential use cases for UAVs have proliferated due to their ability to traverse difficult terrains, reduce labor, and replace fleets of vehicles that require costly maintenance. METHODS: Using a HERMES-generated simulation model, we performed sensitivity analyses to assess the impact of using an unmanned aerial system (UAS) for routine vaccine distribution under a range of circumstances reflecting variations in geography, population, road conditions, and vaccine schedules. We also identified the UAV payload and UAS costs necessary for a UAS to be favorable over a traditional multi-tiered land transport system (TMLTS). RESULTS: Implementing the UAS in the baseline scenario improved vaccine availability (96% versus 94%) and produced logistics cost savings of $0.08 per dose administered as compared to the TMLTS. The UAS maintained cost savings in all sensitivity analyses, ranging from $0.05 to $0.21 per dose administered. The minimum UAV payloads necessary to achieve cost savings over the TMLTS, for the various vaccine schedules and UAS costs and lifetimes tested, were substantially smaller (up to 0.40L) than the currently assumed UAV payload of 1.5L. Similarly, the maximum UAS costs that could achieve savings over the TMLTS were greater than the currently assumed costs under realistic flight conditions. CONCLUSION: Implementing a UAS could increase vaccine availability and decrease costs in a wide range of settings and circumstances if the drones are used frequently enough to overcome the capital costs of installing and maintaining the system. Our computational model showed that major drivers of costs savings from using UAS are road speed of traditional land vehicles, the number of people needing to be vaccinated, and the distance that needs to be traveled.
BACKGROUND: Immunization programs in low and middle income countries (LMICs) face numerous challenges in getting life-saving vaccines to the people who need them. As unmanned aerial vehicle (UAV) technology has progressed in recent years, potential use cases for UAVs have proliferated due to their ability to traverse difficult terrains, reduce labor, and replace fleets of vehicles that require costly maintenance. METHODS: Using a HERMES-generated simulation model, we performed sensitivity analyses to assess the impact of using an unmanned aerial system (UAS) for routine vaccine distribution under a range of circumstances reflecting variations in geography, population, road conditions, and vaccine schedules. We also identified the UAV payload and UAS costs necessary for a UAS to be favorable over a traditional multi-tiered land transport system (TMLTS). RESULTS: Implementing the UAS in the baseline scenario improved vaccine availability (96% versus 94%) and produced logistics cost savings of $0.08 per dose administered as compared to the TMLTS. The UAS maintained cost savings in all sensitivity analyses, ranging from $0.05 to $0.21 per dose administered. The minimum UAV payloads necessary to achieve cost savings over the TMLTS, for the various vaccine schedules and UAS costs and lifetimes tested, were substantially smaller (up to 0.40L) than the currently assumed UAV payload of 1.5L. Similarly, the maximum UAS costs that could achieve savings over the TMLTS were greater than the currently assumed costs under realistic flight conditions. CONCLUSION: Implementing a UAS could increase vaccine availability and decrease costs in a wide range of settings and circumstances if the drones are used frequently enough to overcome the capital costs of installing and maintaining the system. Our computational model showed that major drivers of costs savings from using UAS are road speed of traditional land vehicles, the number of people needing to be vaccinated, and the distance that needs to be traveled.
Authors: Bruce Y Lee; Diana L Connor; Angela R Wateska; Bryan A Norman; Jayant Rajgopal; Brigid E Cakouros; Sheng-I Chen; Erin G Claypool; Leila A Haidari; Veena Karir; Jim Leonard; Leslie E Mueller; Proma Paul; Michelle M Schmitz; Joel S Welling; Yu-Ting Weng; Shawn T Brown Journal: Vaccine Date: 2015-07-23 Impact factor: 3.641
Authors: Shawn T Brown; Benjamin Schreiber; Brigid E Cakouros; Angela R Wateska; Hamadou M Dicko; Diana L Connor; Philippe Jaillard; Mercy Mvundura; Bryan A Norman; Carol Levin; Jayant Rajgopal; Mélanie Avella; Caroline Lebrun; Erin Claypool; Proma Paul; Bruce Y Lee Journal: Vaccine Date: 2014-05-09 Impact factor: 3.641
Authors: Bruce Y Lee; Brigid E Cakouros; Tina-Marie Assi; Diana L Connor; Joel Welling; Souleymane Kone; Ali Djibo; Angela R Wateska; Lionel Pierre; Shawn T Brown Journal: Vaccine Date: 2012-07-10 Impact factor: 3.641
Authors: Tina-Marie Assi; Shawn T Brown; Ali Djibo; Bryan A Norman; Jayant Rajgopal; Joel S Welling; Sheng-I Chen; Rachel R Bailey; Souleymane Kone; Hailu Kenea; Diana L Connor; Angela R Wateska; Anirban Jana; Stephen R Wisniewski; Willem G Van Panhuis; Donald S Burke; Bruce Y Lee Journal: BMC Public Health Date: 2011-06-02 Impact factor: 3.295
Authors: Sebastián Sanz-Martos; María Dolores López-Franco; Cristina Álvarez-García; Nani Granero-Moya; José María López-Hens; Sixto Cámara-Anguita; Pedro Luis Pancorbo-Hidalgo; Inés María Comino-Sanz Journal: Prehosp Disaster Med Date: 2022-06-09 Impact factor: 2.866
Authors: Karl Arne Johannessen; Nina Kristin Steen Wear; Karin Toska; Morten Hansbo; Jens Petter Berg; Erik Fosse Journal: IEEE J Transl Eng Health Med Date: 2021-01-20 Impact factor: 3.316
Authors: Sarah N Cox; Patrick T Wedlock; Sarah W Pallas; Elizabeth A Mitgang; Tatenda T Yemeke; Sarah M Bartsch; Taiwo Abimbola; Sheryl S Sigemund; Aaron Wallace; Sachiko Ozawa; Bruce Y Lee Journal: Vaccine Date: 2021-05-25 Impact factor: 3.641
Authors: Astrid M Knoblauch; Sara de la Rosa; Judith Sherman; Carla Blauvelt; Charles Matemba; Luciana Maxim; Olivier D Defawe; Abdoulaye Gueye; Joanie Robertson; Jesse McKinney; Joe Brew; Enrique Paz; Peter M Small; Marcel Tanner; Niaina Rakotosamimanana; Simon Grandjean Lapierre Journal: BMJ Glob Health Date: 2019-07-30